fluorodeoxyglucose f18 has been researched along with 3-fluoro-2-(4-((2-nitro-1h-imidazol-1-yl)methyl)-1h-1,2,3-triazol-1-yl)propan-1-ol in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Das, M; Dingemans, AC; Even, AJG; Lambin, P; Mottaghy, FM; Oellers, M; Reymen, B; Troost, EGC; van Elmpt, W; Wildberger, JE; Zegers, CML | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and 3-fluoro-2-(4-((2-nitro-1h-imidazol-1-yl)methyl)-1h-1,2,3-triazol-1-yl)propan-1-ol
Article | Year |
---|---|
Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Nitroimidazoles; Oxygen; Oxygen Consumption; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Triazoles | 2016 |